Key Takeaways
- • Dren Bio, a privately held, clinical-stage biotechnology company developing first-in-class antibody therapeutics, closed an oversubscribed $350 million private financing.
- • The round was co-led by Juvia Group and Lightspeed Venture Partners, with new participation from Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Management, and OrbiMed.
- • Existing investors 8VC, SR One, Taiho Ventures, Mission BioCapital, HBM Healthcare Investments, BVF Partners, Aisling Capital, and ArrowMark Partners also participated in the round.
- • Dren Bio's pipeline targets cancer, autoimmune, and other serious diseases, per the company's announcement.
Summary
San Carlos, California-based Dren Bio announced the closing of an oversubscribed $350 million private financing, according to a company announcement published November 2, 2026 and distributed by Massinvestor. The company describes itself as a privately held, clinical-stage biotechnology firm developing first-in-class antibody therapeutics for cancer, autoimmune, and other serious diseases.
The round was co-led by Juvia Group and Lightspeed Venture Partners. It drew an expanded syndicate of new investors, including Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Management, and OrbiMed, indicating broadened institutional and specialist healthcare interest in the company's clinical-stage programs.
Existing backers also took part in the financing. Participating existing investors included 8VC, SR One, Taiho Ventures, Mission BioCapital, HBM Healthcare Investments, BVF Partners, Aisling Capital, and ArrowMark Partners. Their continued participation reflects follow-on support for the company ahead of its next development stage.
The announcement does not disclose valuation, use of proceeds, or specific clinical milestones tied to the financing.
The round was co-led by Juvia Group and Lightspeed Venture Partners. It drew an expanded syndicate of new investors, including Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Management, and OrbiMed, indicating broadened institutional and specialist healthcare interest in the company's clinical-stage programs.
Existing backers also took part in the financing. Participating existing investors included 8VC, SR One, Taiho Ventures, Mission BioCapital, HBM Healthcare Investments, BVF Partners, Aisling Capital, and ArrowMark Partners. Their continued participation reflects follow-on support for the company ahead of its next development stage.
The announcement does not disclose valuation, use of proceeds, or specific clinical milestones tied to the financing.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.